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Five phthalate esters and related compounds (phthalic anhydride, phthalamide, di(2-
ethylhexyl) phthalate, di(2-ethylhexyl) adipate and butyl benzyl phthalate) have been tested for
carcinogenic effects in standard lifetime rodent feeding studies. Groups of 50 male and female
rats and mice were fed diets containing various concentrations of the test chemicals for 102-106
consecutive weeks. The dietary concentrations were estimated to be maximally tolerated doses
and half maximally tolerated doses. All animals that died during the study and all survivors at
the end oftwo years were examined grossly and microscopically for the presence oftumors. The
incidences of animals with tumors at a specific anatomic site in the treated groups and the
controls were compared statistically.
Neither phthalamide nor phthalic anhydride increased tumor incidences in rats or mice.
Di(2-ethylhexyl) phthalate increased the incidences of liver tumors in rats and mice of both
sexes, while di(2-ethylhexyl) adipate caused liver tumors in male and female mice, only. Butyl
benzylphthalatedid notcause tumorsinmale orfemalemice, buttheincidenceofmyelomonocytic
leukemia in butyl benzyl phthalate-treated female rats was significantly greater than that in the
controls. Chemically induced early deaths in the butyl benzyl phthalate-treated male rats
precluded an evaluation of carcinogenic potential in this sex.
Under the conditions of these tests, di(2-ethylhexyl) phthalate was considered to be carcino-
genic in both rats and mice and di(2-ethylhexyl) adipate was considered to be carcinogenic in
mice. The evidence forcarcinogenic effects ofbutyl benzyl phthalate in female rats wasjudgedto
be equivocal because of the variable nature of the incidence of myelomonocytic leukemia in
Fischer 344 rats. Phthalamide and phthalic anhydride did not exhibit carcinogenic effects in
these studies.
Introduction
Di(2-ethylhexyl) phthalate (DEHP), di(2-ethyl-
hexyl) adipate (DEHA) and butyl benzyl phthalate
(BBP) are chemicals frequently added to plastic
formulations to impart flexibility or other charac-
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teristics that determine product use. Such plasti-
cizers do not become part of the polymer matrix
and, under certain use or disposal conditions, can
migrate from the plastic to the external environ-
ment. Although they are not components of the
plastic polymer, plasticizers such as DEHP may
comprise as much as 50% (by weight) of highly
flexible poly(vinyl chloride) products. DEHP is also
used as a hydraulic fluid and as a dielectric fluid.
Phthalate esters, not surprisingly, have become
ubiquitous environmental pollutants.130
Phthalate esters are generally synthesized bythe
condensation of alcohols with phthalic anhydride.
Phthalamide is not used as a plasticizer or in the
synthesis of phthalate esters. Rather, it is an
intermediate in the commercial synthesis oforganic
amines. All five of these chemicals are being
compared, however, because ofsimilaritiesinchem-
ical structure (Fig. 1).
The National Toxicology Program (NTP) and its
predecessor, the National Cancer Institute Carci-
nogenicity Bioassay Program, tests chemicals for
carcinogenic potential as part of a broad initiative
to aid governmental regulatory agencies in protect-
ing the public health. Among the criteria used in
choosing chemicals for testing are volume of pro-
duction, number ofpersons exposed and frequency
and level ofanticipated human exposure. Phthalate
esters and related compounds were tested because
oftheir presence in high concentrations in plastics,
the ubiquity ofphthalate ester-plasticized products
in the home, work and out-of-doors environments
and because of a general lack of previous chronic
toxicity testing with these agents.
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Methods
Male and female rats of the inbred Fischer 344
strain and male and female mice of the hybrid
B6C3F1 strain, obtained from Frederick Cancer
Research Center (Frederick, Md.), were used in all
of the studies. The test chemicals were incorpo-
rated into the feed and supplied to the animals for
102-106 consecutive weeks beginning at 4-6 weeks
of age. In general, each treatment group consisted
of 50 animals of each sex and species at the
estimated maximally tolerated dose (referred to as
the high dose), one-halfofthe estimated maximally
tolerated dose (referred to as the low dose) and
untreated controls (control groups for phthalamide
and phthalic anhydride consisted of 20 animals,
control groups for other chemicals consisted of 50
animals). Estimatedmaximallytolerated doses were
determined by preceeding 90-day subchronic feed-
ing studies.
All animals that died during the study (and were
not excessively cannibalized or autolyzed) and all
survivors at the end ofthe study were subjected to
a gross necropsy and a complete micropathological
examination. Statistical comparisons of the inci-
dences ofanimals with tumors at a specific anatomi-
cal site and of survival and body weight gain were
made using both pairwise comparisons and trend
tests. The basic designs ofthe studies conformed to
the recommendations ofthe National Cancer Insti-
tute (1). Complete technical details of each of the
bioassays are available in the form of technical
reports from the NTP (2-6). Test chemical source,
composition and doses for each ofthe studies were
as follows.
Phthalamide
Phthalamide wasobtainedfromSherwin-Williams,
Inc. (Pittsburgh, Pa.) and demonstrated by HPLC
to be greater than 99% pure. Concentrations of
phthalamide inthe feed were 0 (control), 15,000 and
30,000 ppm for male rats; 0, 5,000 and 10,000 ppm
for female rats; 0, 25,000 and 50,000 ppm for male
mice; and 0, 6,200, 12,500 and 25,000 ppm for
female mice.
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FIGURE 1. Chemical structures of the five compounds tested.
Phthalic Anhydride
Phthalic anhydride was obtained from Koppers
Co. (Pittsburgh, Pa.) and demonstrated by HPLC
to be 98.8% pure. Concentrations ofphthalic anhy-
dride in the feed were 0 (control), 7,500 and 15,000
ppm for male and female rats. Male mice were fed
diets containing 0, 25,000 and 50,000 ppm for the
initial 32 weeks and 0, 12,500 and 25,000 ppm forCARCINOGENICITY TESTING OF PHTHALATE ESTERS
the remainder ofthe study; female mice received 0,
25,000 and 50,000 ppm for 32 weeks and then 0,
6,250 and 12,500 ppm for the rest of the study.
Di(2-ethylhexyl) Phthalate
DEHP was obtained from W. R. Grace and Co.
(Fords, N.J.) and demonstrated by thin-layer and
vapor-phase chromatography to be greater than
99.5% pure. Concentrations of di(2-ethylhexyl)
phthalate in the feed were 0 (control), 6,000 and
12,000 ppm for male and female rats and 0, 3,000
and 6,000 ppm for male and female mice.
Di(2-ethylhexyl) Adipate
Di(2-ethylhexyl)adipate was obtained fromW. R.
Grace and Co. (Fords, N.J.) and demonstrated by
thin-layer and vapor-phase chromatography to be
greater than 98% pure. Concentrations of di(2-
ethylhexyl) adipate in the feed were 0 (control),
12,500 and 25,000 ppm for both male and female
rats and mice.
Butyl Benzyl Phthalate
Butyl benzyl phthalate was obtained from Mis-
souri Solvents and Chemicals (Kansas City, Mo.)
and demonstrated by thin-layer and vapor-phase
chromatography to be greater than 98% pure. Con-
centrations of butyl benzyl phthalate in the feed
were 0 (control), 6,000 and 12,000 ppm for both
male and female rats and mice.
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Results
Phthalamide
Phthalamide administration did notdecreasebody
weight gain norlessen the probability ofsurvival in
either sex ofrats or male mice. Survival for female
mice at the end of two years, however, was only
36% inthe high dose group in comparison to 80% for
the controls. The incidences ofphthalamide-treated
animals with tumors at a specific anatomical site did
not differ significantly from those of the controls.
Phthalic Anhydride
Body weight gains in male rats and in both sexes
of mice were reduced by phthalic anhydride, but
survival in all ofthe treated groups ofanimals was
unaffected. The incidences of phthalic anhydride-
treated animals with tumors at a specific anatomical
site did not differ significantly from those of the
controls.
Di(2-ethylhexyl) Phthalate (DEHP)
DEHP treatment decreased body weight gains
for female mice and for male and female rats.
Animal survival, however, was not compromised
bydietaryingestionofDEHP. Livertumors occurred
in both DEHP-treated rats and mice at incidences
significantly greater than in the respective controls
(Table 1). The incidences of animals with hepa-
tocellular carcinomas was significantly greater for
female rats and for male and female mice treated
with DEHP than for the controls.
Table 1. Incidences of animals with liver tumors in the carcinogenicity bioassay ofdi(2-ethylhexyl) phthalate.'
Incidence
Species Sex Liver tumor Control Low dose High dose
Rat Male Hepatocellular carcinoma 1/50 1/49 5/49
Neoplastic nodule 2/50 5/49 7/49
Hepatocellular carcinoma or neoplastic nodule 3/50 6/49 12/49b
Rat Female Hepatocellular carcinoma 0/50 2/49 8/50C
Neoplastic nodule 0/50 4/49 5/50b
Hepatocellular carcinoma or neoplastic nodule 0/50 6/49b 13/50d
Mouse Male Hepatocellular carcinoma 9/50 14/48 19/50b
Hepatocellular adenoma 6/50 11/48 10/50
Hepatocellular carcinoma or adenoma 14/50 25/48b 29/50c
Mouse Male Hepatocellular carcinoma 0/50 7/50b 17/50d
Hepatocellular adenoma 1/50 5/50 1/50
Hepatocellular carcinoma or adenoma 1/50 12/50b 18/50d
aFischer 344 rats andB6C3F1 mice were fed dietscontaining 0(control), 3,000 (lowdose mice), 6,000 (high dose mice, lowdose rats)
or 12,000ppm (high doserats) ofDEHPforapproximately twoyears. Theratios ofanimalsbearinglivertumors to the totalnumberof
animals examined microscopically are depicted.
bSignificantly greater than controls, p < 0.05.
cSignificantly greater than controls, p < 0.005.
dSignificantly greater than controls, p < 0.001.132
Di(2-ethylhexyl) Adipate (DEHA)
Ingestion of DEHA decreased body weight gains
in male and female rats and mice. Animal survival,
however, was not compromised. The incidences of
tumors atspecificanatomicalsitesinDEHA-treated
rats were not increased relative to the controls, but
liver tumors (hepatocellular carcinomas in female
mice, hepatocellular adenomasinmalemice) occurred
more frequently in DEHA-treated mice than in the
controls (Table 2).
Butyl Benzyl Phthalate (BBP)
Body weight gains in male and female mice and in
female rats were reduced by the ingestion ofBBP,
but survival was unaffected. In contrast, excessive
numbers ofBBP-treated male rats died from appar-
ent internal hemorrhaging after approximately 3
months of exposure. The study in male rats was
terminated early, therefore, and no evaluation of
tumorigenic response in the male rats could be
made. The incidences oftumors at specific anatomi-
cal sites in BBP-treated male and female mice did
not differ significantly from those in controls. The
incidence of animals with myelomonocytic leuke-
mia, however, was greater for the high-dose female
rats than for the controls (Table 3).
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Discussion
Neither phthalamide nor phthalic anhydride was
demonstrated to be carcinogenic for Fischer 344
rats orB6C3F1 hybrid mice, underthe conditions of
the standard bioassay, since theincidences ofchem-
ically treated animals with tumors at a specific
anatomical site did not differ significantly from
those in controls.
DEHP was considered to be carcinogenic in both
Fischer 344 rats and B6C3F1 mice because of the
significantly increased incidences in test chemical-
treatedanimalsofhepatocellularcarcinomasinmale
and female mice and infemale rats. The incidence of
male rats with either hepatocellular carcinomas or
neoplastic nodules (total liver tumors) was also
significantly greater in the high-dose group than in
the controls. The absence of nonneoplastic lesions
in the liver and the failure of DEHP to reduce
survival suggests that the liver tumors were not
caused by an indirect hepatotoxic effect.
DEHA was considered to be carcinogenic in
B6C3F1 mice because of the greater incidence in
test chemical-treated animals ofhepatocellular car-
cinomas in female mice. Since only the incidence of
hepatocellular adenomas (benign liver tumors), not
that of hepatocellular carcinomas (malignant liver
tumors), was significantly increased in the male
Table 2. Incidences of mice with liver tumors in the carcinogenicity bioassay ofdi(2-ethylhexyl) adipate.a
Incidence
Species Liver tumor Control Low dose High dose
Male Hepatocellular carcinoma 7/50 12/49 12/49
Hepatocellular adenoma 6/50 8/49 15/49b
Hepatocellular carcinoma or adenoma 13/50 20/49 27/49c
Female Hepatocellular carcinoma 1/50 14250d 12/49c
Hepatocellular adenoma 2/50 5/50 6/49
Hepatocellular carcinoma or adenoma 3/50 19/50d 18/49d
aB6C3Fj mice were fed diets containing 0 (control), 12,000 (low dose) or 25,000 ppm (high dose) of DEHA for approximately two
years. The ratios of mice bearing liver tumors to the total number of mice examined microscopically are depicted. bSignificantly greater than controls, p < 0.05.
cSignificantly greater than controls, p < 0.005.
dSignificantly greater than controls, p < 0.001.
Table 3. Incidences of female rats with tumors of the hematopoietic system in the carcinogenicity bioassay of butyl benzyl
phthlate.a
Incidence
Hematopoietic system tumor Control Low dose High dose
Myelomonocytic leukemia 7/49 7/49 18/50b
Lymphoma 0/49 0/49 1/50
Myelomonocytic leukemia or lymphoma 7/49 7/49 19/50b
aFemale Fischer 344 rats were fed diets containing0(controls), 6,000 (lowdose) or 12,000ppm(highdose) ofBBPforapproximately
two years. The ratios of female rats bearing tumors of the hematopoietic system to the total number of female rats examined
microscopically are depicted.
bSignificantly greater than controls, p < 0.05.CARCINOGENICITY TESTING OF PHTHALATE ESTERS 133
mice, the data were judged to be evidence ofprob-
ablecarcinogenicity ofDEHAinmale B6C3F1mice.
Carcinogenic effects of DEHA in Fischer 344 rats
was not demonstrated.
Although ofstatistical significance, the increased
incidence of myelomonocytic leukemia in female
rats receiving the high dose ofBBP was considered
to be of equivocal biological significance due to
considerable variation in the background incidence
of myelomonocytic leukemia in Fischer 344 rats.
Moreover, the organ distribution and cytological
characteristics of the leukemia occurring in the
high-dose BBP-treated female rats did not differ
from that in the controls, indicatingthat the form of
leukemia in the treated rats was the same as that
occurring naturally in this strain of rat. The data,
therefore, were considered to be evidence ofprob-
able carcinogenicity of BBP in female Fischer 344
rats. The study was judged to be inadequate in
male ratsbecause ofchemically induced earlydeaths.
No evidence of BBP carcinogenicity was observed
in B6C3F1 mice.
In summary, two ofthe five phthalate esters and
related compounds tested by the National Toxicol-
ogy Program and the National Cancer Institute for
carcinogenic potential in rodent feeding studies,
DEHP and DEHA, werejudged to be carcinogenic.
DEHP caused liver tumors in both rats and mice,
while DEHA caused liver tumors in mice, only.
Because of the similarities in chemical structure
and the site of induced tumor formation, it can be
speculated that DEHP and DEHA act through
similar mechanisms. BBP was causally associated
with an increased frequency ofmyelomonocytic leu-
kemia in female Fischer344 rats, butthe character-
istics of the induced tumor precluded an unequivo-
cal evaluation of carcinogenic potential. The final
twochemicals, phthalamide andphthalic anhydride,
exhibited no evidence of carcinogenicity in these
studies.
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